Is the cancer immunotherapy market up for disruption as AstraZeneca, Regeneron-Sanofi, cheaper Chinese offerings line up?

In the cancer immunotherapy market, Merck & Co. has established its Keytruda as the absolute leader. But AstraZeneca, a partnership between Regeneron and Sanofi plus several Chinese firms and their Western collaborators are all lining up their products for the most desirable piece of the cake: non-small cell lung cancer (NSCLC).